ADTX and EVFM Related Headlines
Go Back- Evofem shareholders reject merger with Aditxt
- Evofem Announces Voting Results from Special Meeting of Stockholders
- Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms
- Evofem expects merger approval at Sept. 26 stockholder meeting
- Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting
- Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law
- FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis
- Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update
- Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference
- Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy
ADTX and EVFM Related Press Releases
Go Back- Evofem Announces Voting Results from Special Meeting of Stockholders
- Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms
- Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting
- Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law
- FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis
- Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update
- Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference
- Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy
